HK1018481A1 - Lentiviral vectors - Google Patents
Lentiviral vectorsInfo
- Publication number
- HK1018481A1 HK1018481A1 HK99103561A HK99103561A HK1018481A1 HK 1018481 A1 HK1018481 A1 HK 1018481A1 HK 99103561 A HK99103561 A HK 99103561A HK 99103561 A HK99103561 A HK 99103561A HK 1018481 A1 HK1018481 A1 HK 1018481A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- lentiviral vectors
- vector particles
- provirus
- letiviruses
- ltr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9621680.9A GB9621680D0 (en) | 1996-10-17 | 1996-10-17 | Lentiviral vectors |
PCT/GB1997/002858 WO1998017816A1 (fr) | 1996-10-17 | 1997-10-17 | Vecteurs lentiviraux |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1018481A1 true HK1018481A1 (en) | 1999-12-24 |
Family
ID=10801598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK99103561A HK1018481A1 (en) | 1996-10-17 | 1999-08-17 | Lentiviral vectors |
Country Status (18)
Country | Link |
---|---|
US (1) | US6235522B1 (fr) |
EP (1) | EP0939827B1 (fr) |
JP (1) | JP2001502903A (fr) |
KR (1) | KR20000049250A (fr) |
CN (1) | CN1195864C (fr) |
AT (1) | ATE520783T1 (fr) |
AU (1) | AU737801B2 (fr) |
BG (1) | BG103334A (fr) |
CA (1) | CA2268271A1 (fr) |
CZ (1) | CZ137299A3 (fr) |
GB (2) | GB9621680D0 (fr) |
HK (1) | HK1018481A1 (fr) |
HU (1) | HUP0000442A3 (fr) |
IL (1) | IL128564A0 (fr) |
NO (1) | NO991742D0 (fr) |
NZ (1) | NZ334522A (fr) |
PL (1) | PL332876A1 (fr) |
WO (1) | WO1998017816A1 (fr) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924123B2 (en) * | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
DE69829471T2 (de) | 1997-05-13 | 2006-04-13 | University Of North Carolina At Chapel Hill | Auf lentivirus basierende gentransfer-vektoren |
FI112580B (fi) | 1997-06-27 | 2003-12-15 | Nokia Corp | Kutsunsiirron reititys peruspalvelukohtaisesti |
EP1017797B1 (fr) | 1997-09-24 | 2005-06-22 | The Regents Of The University Of California | Vecteurs de lentivirus non originaires de primates et systemes d'encapsidation |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
WO1999067400A1 (fr) | 1998-06-24 | 1999-12-29 | Musc Foundation For Research Development | Ribozymes specifiques aux tissus et a l'arn cible |
US6958226B1 (en) | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
IL146144A0 (en) | 1999-04-29 | 2002-07-25 | Cell Genesys Inc | Method and means for producing high titer, safe, recombinant lentivirus vectors |
EP1083230A1 (fr) * | 1999-09-10 | 2001-03-14 | Academisch Medisch Centrum Amsterdam | Replicon viral et virus dépendant d'agents inducteurs |
JP4540033B2 (ja) | 1999-10-22 | 2010-09-08 | サノフィ パストゥール リミテッド | 腫瘍抗原に対する免疫応答を誘発および/または増強する方法 |
US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
EP1702983A3 (fr) | 2000-04-13 | 2007-01-10 | Medical University of South Carolina | Agents toxiques, ribozymes, ADNzymes et oligonucléotides antisens spécifiques des tissus et des pathogènes et procédé d'utilisation associé |
DE60124899T2 (de) | 2000-05-10 | 2007-08-16 | Sanofi Pasteur Ltd., Toronto | Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen |
WO2001090391A2 (fr) | 2000-05-19 | 2001-11-29 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilisation de sequences non virales pour transfert d'un brin d'adn negatif et reconstitution d'un gene |
CA2426647A1 (fr) * | 2000-10-20 | 2002-05-02 | Whitehead Institute For Biomedical Research | Vecteurs d'expression et leurs utilisations |
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
AU2002307393A1 (en) * | 2001-04-20 | 2002-11-05 | The Salk Institute For Biological Studies | Inducible expression of transfected genes |
US20030039636A1 (en) * | 2001-05-01 | 2003-02-27 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (SIN) lentiviral vectors |
WO2003012054A2 (fr) | 2001-08-02 | 2003-02-13 | Institut Clayton De La Recherche | Procedes et compositions relatifs a des systemes production ameliores de vecteurs lentiviraux |
EP1438075A4 (fr) * | 2001-10-02 | 2006-04-19 | Inst Clayton De La Rech | Procedes et compositions se rapportant a des vecteurs lentiviraux a expression reduite et leurs applications |
EP1504108B1 (fr) | 2002-02-01 | 2013-04-17 | Oxford Biomedica (UK) Limited | Vecteur lentivirale |
AU2004280608B2 (en) * | 2002-04-09 | 2012-04-05 | Sanofi Pasteur, Inc. | Modified CEA/B7 vector |
DE60315628T2 (de) | 2002-04-09 | 2008-06-05 | Sanofi Pasteur Ltd., Toronto | Modifizierte cea nucleinsäure und expressionsvektoren |
CA2484166C (fr) * | 2002-04-26 | 2011-11-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Glycoproteines chimeriques ameliorees et vecteurs lentiviraux pseudotypes ameliores |
AU2003288686A1 (en) * | 2002-11-22 | 2004-06-18 | Institut Clayton De La Recherche | Compositions and systems for the regulation of genes |
WO2005030927A2 (fr) * | 2003-09-23 | 2005-04-07 | Uab Research Foundation | Procedes et compositions pour le controle de l'inflammation in vivo |
WO2005118809A2 (fr) * | 2004-04-29 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Procedes et compositions pour ameliorer les proprietes d'adhesion cellulaire |
US20060292159A1 (en) * | 2005-06-08 | 2006-12-28 | Ranscht Barbara E | Methods for the inhibition of neovascularization and cancer metastasis |
GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
WO2013184209A1 (fr) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif destiné à être utilisé dans des méthodes de traitement de sujets atteints d'une maladie neurodégénérative |
KR101554678B1 (ko) | 2012-10-19 | 2015-09-21 | 영남대학교 산학협력단 | 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도 |
HUE053136T2 (hu) | 2013-02-15 | 2021-06-28 | Bioverativ Therapeutics Inc | Optimizált VIII. faktor gén |
BR112015022189A2 (pt) * | 2013-03-13 | 2017-11-21 | Katsura Misako | microvesícula, método para produção e uso da mesma |
EP3160478A4 (fr) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Gène du facteur ix optimisé |
EP3031923A1 (fr) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux |
CN109072214B (zh) | 2016-02-01 | 2023-02-17 | 比奥贝拉蒂治疗公司 | 优化的因子viii基因 |
EP3443001A4 (fr) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | Systèmes de biocircuits régulés |
BR112019007309A2 (pt) | 2016-10-12 | 2019-07-02 | Bioverativ Usa Inc | anticorpos anti-c1s e métodos de uso dos mesmos |
CA3042989A1 (fr) | 2016-11-07 | 2018-05-11 | Junho Chung | Anticorps anti- famille avec similarite de sequence 19, element a5 et leur procede d'utilisation |
CA3067923A1 (fr) | 2017-06-27 | 2019-01-03 | Neuracle Science Co., Ltd. | Anticorps anti-fam19a5 et leurs utilisations |
KR102573257B1 (ko) | 2017-06-27 | 2023-09-01 | 주식회사 뉴라클사이언스 | 섬유증의 치료를 위한 항-fam19a5 항체의 용도 |
WO2019003162A1 (fr) | 2017-06-27 | 2019-01-03 | Neuracle Science Co., Ltd. | Utilisation d'anticorps dirigés contre une famille à similarité de séquence 19, membre a5, pour le traitement du glaucome |
KR102454460B1 (ko) | 2017-06-27 | 2022-10-17 | 주식회사 뉴라클사이언스 | 암 치료를 위한 항-fam19a5 항체의 용도 |
EP3648776A4 (fr) | 2017-07-06 | 2021-04-07 | The Medical College of Wisconsin, Inc. | Nouvelle stratégie d'enrichissement in vitro et in vivo ciblant les lymphocytes dérivés de csh transduites par un vecteur pour la thérapie de troubles |
JP7369121B2 (ja) | 2017-10-11 | 2023-10-25 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 補体活性を誘発する方法 |
US20210038744A1 (en) | 2018-02-01 | 2021-02-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor viii |
KR20200118913A (ko) | 2018-04-24 | 2020-10-16 | 주식회사 뉴라클사이언스 | 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도 |
KR20200122409A (ko) | 2018-05-10 | 2020-10-27 | 주식회사 뉴라클사이언스 | 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법 |
EP3841124A4 (fr) | 2018-06-29 | 2022-03-23 | ApitBio, Inc. | Anticorps anti-l1cam et leurs utilisations |
AU2019379325A1 (en) | 2018-11-16 | 2021-06-03 | Genexine, Inc. | Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor |
BR112021010047A2 (pt) | 2018-12-06 | 2021-08-24 | Bioverativ Therapeutics Inc. | Uso de vetores lentivirais expressando o fator ix |
KR20200071198A (ko) | 2018-12-10 | 2020-06-19 | 네오이뮨텍, 인코퍼레이티드 | Nrf2 발현 조절 기반 T 세포 항암면역치료법 |
US20210113634A1 (en) | 2019-09-30 | 2021-04-22 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
EP4090430A1 (fr) | 2020-01-13 | 2022-11-23 | Neoimmune Tech, Inc. | Procédé de traitement d'une tumeur au moyen d'une combinaison d'une protéine il-7 et d'un anticorps bispécifique |
WO2021151001A1 (fr) | 2020-01-22 | 2021-07-29 | Outpace Bio, Inc. | Polypeptides chimères |
WO2021151006A2 (fr) | 2020-01-22 | 2021-07-29 | Outpace Bio, Inc. | Polypeptides chimériques |
AU2021217373A1 (en) | 2020-02-05 | 2022-08-04 | Neoimmunetech, Inc. | Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells |
US20220033849A1 (en) | 2020-06-24 | 2022-02-03 | Bioverativ Therapeutics Inc. | Methods for the purification of viral vectors |
WO2022087453A1 (fr) | 2020-10-22 | 2022-04-28 | Lyell Immunopharma, Inc. | Récepteurs d'activation chimériques |
US20230398184A1 (en) | 2020-10-26 | 2023-12-14 | Neoimmunetech, Inc. | Methods of inducing stem cell mobilization |
US20240101629A1 (en) | 2020-11-02 | 2024-03-28 | Neoimmunetech, Inc. | Use of interleukin-7 for the treatment of coronavirus |
EP4240408A1 (fr) | 2020-11-05 | 2023-09-13 | Neoimmunetech, Inc. | Procédé de traitement d'une tumeur au moyen d'une combinaison d'une protéine il-7 et d'un vaccin nucléotidique |
WO2022251644A1 (fr) | 2021-05-28 | 2022-12-01 | Lyell Immunopharma, Inc. | Cellules immunitaires déficientes en nr4a3 et leurs utilisations |
AU2022286947A1 (en) | 2021-06-02 | 2023-12-14 | Lyell Immunopharma, Inc. | NR4A-deficient cells expressing c-Jun and uses thereof |
CA3232988A1 (fr) | 2021-09-30 | 2023-04-06 | Bioverativ Therapeutics Inc. | Acides nucleiques codant pour des polypeptides du facteur viii a immunogenicite reduite |
WO2023081923A1 (fr) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Inhibiteurs du récepteur du facteur de croissance dérivé des plaquettes (pdgfr) alpha et leurs utilisations |
WO2023130081A1 (fr) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Procédé de traitement d'une tumeur avec une combinaison d'une protéine il-7 et d'un antagoniste du vegf |
WO2024026490A1 (fr) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucléotides codant pour des antigènes liés et leurs utilisations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604114A (en) * | 1986-05-20 | 1997-02-18 | Dana-Farber Cancer Institute | Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use |
AU2007392A (en) * | 1991-05-29 | 1993-01-08 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Eukaryotic expression vectors with regulation of rna processing |
WO1995030755A1 (fr) * | 1994-05-10 | 1995-11-16 | Hisamitsu Pharmaceutical Co., Inc. | Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production |
WO1995032300A1 (fr) * | 1994-05-23 | 1995-11-30 | University Of Medicine & Dentistry Of New Jersey | Destruction biologique selective des cellules tumorales |
US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
ES2198479T3 (es) * | 1995-03-09 | 2004-02-01 | Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh | Vectores que llevan genes terapeuticos codificantes de peptidos antimicrobianos para terapia genica. |
GB9510272D0 (en) | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
WO1997048277A1 (fr) | 1996-06-20 | 1997-12-24 | The Salk Institute For Biological Studies | Vecteurs retroviraux a structure modulaire et leurs utilisations |
-
1996
- 1996-10-17 GB GBGB9621680.9A patent/GB9621680D0/en active Pending
-
1997
- 1997-10-17 JP JP10519087A patent/JP2001502903A/ja not_active Ceased
- 1997-10-17 AU AU47123/97A patent/AU737801B2/en not_active Expired
- 1997-10-17 CZ CZ991372A patent/CZ137299A3/cs unknown
- 1997-10-17 CA CA002268271A patent/CA2268271A1/fr not_active Abandoned
- 1997-10-17 KR KR1019990703355A patent/KR20000049250A/ko not_active Application Discontinuation
- 1997-10-17 HU HU0000442A patent/HUP0000442A3/hu unknown
- 1997-10-17 WO PCT/GB1997/002858 patent/WO1998017816A1/fr not_active Application Discontinuation
- 1997-10-17 EP EP97909437A patent/EP0939827B1/fr not_active Expired - Lifetime
- 1997-10-17 NZ NZ334522A patent/NZ334522A/en not_active IP Right Cessation
- 1997-10-17 PL PL97332876A patent/PL332876A1/xx unknown
- 1997-10-17 US US09/284,011 patent/US6235522B1/en not_active Expired - Lifetime
- 1997-10-17 AT AT97909437T patent/ATE520783T1/de not_active IP Right Cessation
- 1997-10-17 IL IL12856497A patent/IL128564A0/xx unknown
- 1997-10-17 GB GB9903117A patent/GB2331522B/en not_active Expired - Lifetime
- 1997-10-17 CN CNB971988838A patent/CN1195864C/zh not_active Expired - Lifetime
-
1999
- 1999-04-13 NO NO991742A patent/NO991742D0/no not_active Application Discontinuation
- 1999-04-14 BG BG103334A patent/BG103334A/xx unknown
- 1999-08-17 HK HK99103561A patent/HK1018481A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
GB9621680D0 (en) | 1996-12-11 |
EP0939827A1 (fr) | 1999-09-08 |
JP2001502903A (ja) | 2001-03-06 |
NO991742L (no) | 1999-04-13 |
GB2331522B (en) | 2001-05-23 |
GB9903117D0 (en) | 1999-04-07 |
CA2268271A1 (fr) | 1998-04-30 |
PL332876A1 (en) | 1999-10-25 |
NZ334522A (en) | 2001-11-30 |
CZ137299A3 (cs) | 1999-07-14 |
HUP0000442A2 (hu) | 2000-06-28 |
KR20000049250A (ko) | 2000-07-25 |
AU737801B2 (en) | 2001-08-30 |
CN1234075A (zh) | 1999-11-03 |
CN1195864C (zh) | 2005-04-06 |
NO991742D0 (no) | 1999-04-13 |
US6235522B1 (en) | 2001-05-22 |
HUP0000442A3 (en) | 2001-09-28 |
GB2331522A (en) | 1999-05-26 |
BG103334A (en) | 2000-06-30 |
WO1998017816A1 (fr) | 1998-04-30 |
AU4712397A (en) | 1998-05-15 |
IL128564A0 (en) | 2000-01-31 |
EP0939827B1 (fr) | 2011-08-17 |
ATE520783T1 (de) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2331522B (en) | Lentiviral vectors | |
GB9510272D0 (en) | Retroviral vectors | |
EP0702716A4 (fr) | Therapie genique ribozymique contre l'infection par le vih et contre le sida | |
AU4712297A (en) | Retroviral vectors | |
NZ500740A (en) | Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV) | |
CA2311641A1 (fr) | Vecteurs retroviraux pseudotypes a proteines de surface d'enveloppe et procede de fabrication desdits vecteurs pour le transfert selectif de genes | |
EP0801575A4 (fr) | Vecteurs retroviraux destines a l'expression dans les cellules embryonnaires | |
NO983375D0 (no) | Retroviral vektor og anvendelse derav i genterapi | |
AU4712497A (en) | Retroviral vectors | |
EP0276591A3 (en) | Viral vector and recombinant dna coding for the p25 protein of the aids virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PE | Patent expired |
Effective date: 20171016 |